Ogura, Yuichiro
Kondo, Mineo
Kadonosono, Kazuaki
Shimura, Masahiko
Kamei, Motohiro
Tsujikawa, Akitaka
Article History
Received: 15 November 2018
Accepted: 17 June 2019
First Online: 19 August 2019
Change Date: 22 April 2020
Change Type: Correction
Change Details: In the original publication, under section, BRVO treatment practice pattern, the sentence in p. 369 was published as.
Conflicts of interest
: Y. Ogura, Consultant fee (Bayer, Alcon, Janssen Pharma, Kowa, Novartis, Sanwa Kagaku, Senju, Wakamoto), Speaker Fee (Santen, Topcon, Wakamoto), Grant (Novartis, Santen); M. Kondo, Grant (Novartis); K. Kadonosono, None; M. Shimura, None; M. Kamei, Speaker fee (Alcon, AMO, Bayer, Bausch & Lomb, Ellex, HOYA, Johnson & Johnson, Kowa, Nidek, Novartis, Otsuka, Pfizer, Santen, Senju), Consultant fee (Astellas, HOYA, Nidek, Senju), Grant (Alcon, AMO, Bayer, HOYA, Kowa, Nidek, Novartis, Otsuka, Pfizer, Santen, Senju); A. Tsujikawa, Lecture fee (Pfizer, Bayer, Santen, Novartis, Senju, Alcon, Nidek, AMO, Kowa, Chugai, Sanwa Kagaku, Astellas Pharma, Johnson & Johnson, Alcon Pfarma, Otsuka, Ezai), Grant (Pfizer, Bayer, Japan Society for the Promotion of Science, Santen, Novartis, Senju, Alcon, AMO, Hoya, Kowa, Alcon Pharma, Otsuka).